Study S002831

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RT-114 in Healthy Volunteers

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06891287
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 60
Start: 2025-12-30
Primary completion: 2026-12-01
Lead sponsor: RANI Therapeutics
Conditions: Obesity
Interventions: COMBINATION_PRODUCT:RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity; DRUG:PG-102; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

To evaluate safety and tolerability of RT-114 by assessing treatment emergent adverse events (TEAEs) [Single dose and 8 weeks of repeat dosing]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.